ArticleGut microbes2025
BroadAMP-GPT: AI-Driven generation of broad-spectrum antimicrobial peptides for combating multidrug-resistant ESKAPE pathogens.
Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Combating antimicrobial resistance through multimodal data via artificial intelligence.One health (Amsterdam, Netherlands) · 2026Review
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- Discovery of potent low-toxicity antimicrobial peptides through diffusion modeling.Nature communications · 2026Article
- AI-Driven Discovery and Design of Antimicrobial Peptides: Progress, Challenges, and Opportunities.Probiotics and antimicrobial proteins · 2026Review
- Prediction of minimum inhibitory concentration of antibacterial peptides using geometric graph networks and dynamic loss functions.Briefings in bioinformatics · 2026Article
- ANIA: an inception-attention network for predicting minimum inhibitory concentration of antimicrobial peptides.Briefings in bioinformatics · 2026Article
- Artificial intelligence applications in biofilm research: computational approaches for biofilm analysis and antimicrobial prediction.Frontiers in microbiology · 2026Review
- Artificial Intelligence in Proteins and Peptides: A Comprehensive Overview from Hybrid Modeling to Deep Learning.Current protein & peptide science · 2026Article
- tsAMP: a strain-level antimicrobial peptide identification framework based on large language models and pathogen genomic variation.Frontiers in microbiology · 2026Article
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) are promising candidates to address the global antimicrobial resistance crisis, yet their traditional design remains labor-intensive and inefficient. Here, we developed BroadAMP-GPT, an integrated computational-experimental framework that combines AI-driven generation, multi-tiered screening, and experimental validation to rapidly discover potent AMPs with broad-spectrum activity. Using this platform, 57% of AI-generated candidates exhibited potent efficacy against ESKAPE pathogens - key culprits of multidrug-resistant infections. An outstanding candidate, AMP_S13, demonstrated exceptional stability under diverse physiological conditions, including extreme pH (2-10), proteolytic exposure, and elevated temperatures, while maintaining minimal cytotoxicity and low hemolytic activity. AMP_S13 also showed robust
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.